Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effects of Rosuvastatin on Physiological Adaptation and Safety During Regular Long-Distance Running Training
NCT07401017Not yet recruiting
- Sponsor
- Taipei Medical University WanFang Hospital
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of rosuvastatin in dyslipidemia (2 arms), sponsored by Taipei Medical University WanFang Hospital. Primary endpoints: Maximal Oxygen Uptake at Month 3, Aerobic Threshold at Month 3 and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
rosuvastatin
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT07401017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401017.